Abstract: Albumin-bound paclitaxel is a novel formulation of paclitaxel with albumin as its solvent. Compare to the conventional paclitaxel formulation （solvent is polyoxyethylene castor oil and ethanol），its anti-tumor capability is more effective and hematologic toxicity，severe allergic reaction and other side effects are less. In recent years，albumin-bound paclitaxel are widely used on clinical studies of gynecologic oncology. There are three Phase Ⅱ clinical studies currently reported on ovarian cancer，nanoparticle albumin-bound paclitaxel in platinum-sensitive patients and platinum-resistant patients with ovarian，peritoneal，or fallopian tube canceral and bevacizumab with albumin-bound paclitaxel in patients with recurrent，platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma,which have shown the efficacy and tolerated adverse reactions. The study reported a phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer and point out that albumin-bound paclitaxel is a considering drug with little side effects. In short，there is only a few study on albumin-bound paclitaxel in gynecologic oncology until now and we need more further study.

Key words: Paclitaxel, Uterine cervical neoplasms, Ovarian neoplasms, Uterine neoplasms, Carcinoma, Sarcoma